Affimed (NASDAQ:AFMD) Upgraded at StockNews.com

StockNews.com upgraded shares of Affimed (NASDAQ:AFMDGet Rating) from a sell rating to a hold rating in a report published on Monday morning.

A number of other analysts also recently weighed in on the company. Wells Fargo & Company reiterated an overweight rating on shares of Affimed in a research report on Thursday, August 18th. Stifel Nicolaus downgraded Affimed from a buy rating to a hold rating and dropped their price objective for the stock from $9.00 to $2.00 in a research report on Monday, October 10th. Finally, Cantor Fitzgerald reaffirmed an overweight rating on shares of Affimed in a report on Wednesday, September 21st. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of $7.50.

Affimed Stock Down 1.4 %

AFMD stock opened at $2.11 on Monday. The business’s 50 day simple moving average is $1.93 and its 200 day simple moving average is $2.58. The firm has a market capitalization of $260.42 million, a PE ratio of -3.35 and a beta of 2.19. Affimed has a 1-year low of $1.40 and a 1-year high of $7.13. The company has a current ratio of 5.65, a quick ratio of 5.63 and a debt-to-equity ratio of 0.07.

Institutional Trading of Affimed

A number of institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SNC increased its position in shares of Affimed by 94.1% during the third quarter. BNP Paribas Arbitrage SNC now owns 61,261 shares of the biopharmaceutical company’s stock valued at $126,000 after acquiring an additional 29,704 shares during the last quarter. State Street Corp grew its position in shares of Affimed by 5.0% in the third quarter. State Street Corp now owns 2,355,701 shares of the biopharmaceutical company’s stock valued at $4,853,000 after purchasing an additional 112,217 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Affimed by 14.0% in the third quarter. Vanguard Group Inc. now owns 1,398,231 shares of the biopharmaceutical company’s stock valued at $2,880,000 after purchasing an additional 171,258 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Affimed by 63.4% in the third quarter. Price T Rowe Associates Inc. MD now owns 22,174 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 8,604 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Affimed by 10.6% during the third quarter. Bank of New York Mellon Corp now owns 362,413 shares of the biopharmaceutical company’s stock valued at $746,000 after buying an additional 34,641 shares during the period. 71.08% of the stock is owned by hedge funds and other institutional investors.

About Affimed

(Get Rating)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.

Featured Stories

Analyst Recommendations for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.